# Hikma Pharmaceuticals Plc All businesses performing well

- Link: https://www.directorstalkinterviews.com/hikma-pharmaceuticals-plc-all-businesses-performing-well/412789863
- Published: 2019-08-09T07:19:16+01:00
- Author: Amilia Stone

**[Hikma Pharmaceuticals Plc](https://www.directorstalkinterviews.com/ftse-company/hikma-pharmaceuticals/hik.l)**(
LON:HIK), the multinational pharmaceutical company, today reported its interim results
for the six months ended 30 June 2019. 

**H1 2019 core**^(**1**)** results summary**

·   Group core revenue of $1,043 million, up 7%

·   Group core operating profit of $246 million, up 15%

·   Core basic earnings per share of 72.7 cents, up 18%

·   Raising full year expectations for Generics and now expect Injectables to be
towards the higher end of our previous full year guidance range

**H1 2019 reported results summary**

·   Group revenue of $1,047 million, up 7%

·   Group operating profit of $238 million, up 37%

·   Cashflow from operating activities of $187 million (H1 2018: $185 million)

·   Net debt of $361 million (December 2018: $361 million) and low leverage ratios
maintained

·   Basic earnings per share of 76.4 cents, up 74%

·   Interim dividend increased 17% to 14 cents per share

**Strategic highlights**

·   Appointed new Chief Scientific Officer, strengthening our R&D capabilities

·   Launched 37 new products across all markets, expanding our global product portfolio

·   Signed 7 product licensing agreements for the US and MENA

·   Entered into long-term supply agreement with Civica Rx for essential injectable
products

> **Siggi Olafsson, Chief Executive Officer of Hikma, said**: 
> “All of our businesses are performing well.  We are delivering more from our unique
> and diversified business model, leading market positions and high-quality operations
> to drive strong organic growth.   Our good half-year financial results demonstrate
> the breadth and resilience of our marketed portfolio, successful pipeline launches
> and actions we’ve taken to reduce costs and increase efficiencies.  During the
> first half, we continued to focus on pipeline development.  We increased investment
> in our R&D programmes, added new products through partnerships and strengthened
> our R&D team.    
> I am very pleased with our first half performance, and the increase in our full
> year guidance reflects our confidence for the remainder of the year.”

**Summary financials**

| **Core results ** | **H1 2019$million** | H1 2018$million | Change | Constant currencychange | 
| Core revenue | **1,043** | 979 | 7% | 7% | 
| Core operating profit | **246** | 214 | 15% | 15% | 
| Core EBITDA^(2) | **288** | 252 | 14% | 14% | 
| Core profit attributable to shareholders | **176** | 148 | 19% | 20% | 
| Core basic earnings per share (cents) | **72.7** | 61.4 | 18% | 19% |

| **Reported results ** | **H1 2019$million** | H1 2018$million | Change | Constant currencychange | 
| Revenue | **1,047** | 979 | 7% | 8% | 
| Operating profit | **238** | 174 | 37% | 37% | 
| EBITDA | **297** | 230 | 29% | 30% | 
| Profit attributable to shareholders | **185** | 106 | 75% | 75% | 
| Basic earnings per share (cents) | **76.4** | 44.0 | 74% | 75% |

^(_1_)_ Core results throughout the document are presented to show the underlying
performance of the Group, excluding the exceptional items and other adjustments 
set out in note 4.  Core results are a non-IFRS measure and a reconciliation to 
reported IFRS measures is provided on page 12_

^(_2_)_ EBITDA is earnings before interest, tax, depreciation, amortisation and 
impairment charge; EBITDA is a non-IFRS measure and a reconciliation to reported
IFRS measures is provided on page 13_

Share on:
